Reams G P, Bauer J H, Lau A
Department of Medicine, University of Missouri School of Medicine, Columbia 65212.
J Clin Pharmacol. 1987 Feb;27(2):118-21. doi: 10.1002/j.1552-4604.1987.tb02171.x.
The effects of betaxolol, a long-acting, lipid-soluble, cardioselective, beta-adrenergic antagonist on renal function have not been previously reported. The present study was designed to prospectively assess the acute and chronic antihypertensive, humoral, and renal response to betaxolol, administered once daily, to patients with essential hypertension. After a four-week placebo run-in period, 13 patients with essential hypertension were treated with betaxolol monotherapy for a total of eight months. Results indicate that blood pressure is reduced, and renal function remains stable. These findings are consistent with previous observations with other beta-adrenergic antagonists.
长效、脂溶性、心脏选择性β-肾上腺素能拮抗剂倍他洛尔对肾功能的影响此前尚未见报道。本研究旨在前瞻性评估每日给药一次的倍他洛尔对原发性高血压患者的急性和慢性降压、体液及肾脏反应。在为期四周的安慰剂导入期后,13例原发性高血压患者接受倍他洛尔单药治疗,共治疗八个月。结果表明血压降低,且肾功能保持稳定。这些发现与此前使用其他β-肾上腺素能拮抗剂的观察结果一致。